Compare SPCB & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | VERU |
|---|---|---|
| Founded | 1988 | 1971 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 41.7M |
| IPO Year | 2004 | 1996 |
| Metric | SPCB | VERU |
|---|---|---|
| Price | $7.91 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 37.8K | ★ 49.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.13 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.10 | $0.36 |
| 52 Week High | $13.57 | $4.59 |
| Indicator | SPCB | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 46.03 |
| Support Level | $7.75 | $2.15 |
| Resistance Level | $9.86 | $2.70 |
| Average True Range (ATR) | 0.39 | 0.13 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 13.27 | 16.67 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.